Results 71 to 80 of about 19,278,359 (237)
Immune potentiating effects of the HDAC inhibitor Zabadinostat on human immune and tumor cells
Zabadinostat (CXD101) is a second‐generation class I histone deacetylase inhibitor (HDACi). We show that Zabadinostat activates human T cells and natural killer cells while reducing frequencies and function of regulatory T cells. Zabadinostat also increases T cell stemness and modulates tumor cell phenotype to potentially enhance immune recognition ...
Stephanie C. Pitts +15 more
wiley +1 more source
Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley +1 more source
Background and Objectives: Hemolytic disease of the fetus and newborn (HDFN) occurs as a result of maternal sensitization to paternal antigens. Studies have shown that the immunoglobulin G (IgG) subclass in maternal serum – particularly the presence of ...
A. A. Arif Vaheedu +3 more
doaj +1 more source
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Anti-SAA and anti-SAA1α levels in IVIg.
Octagam IVIg was serially diluted in sample dilution buffer (dilution range of 1.56–50 μg/ml) and analyzed for the presence of anti-SAA and anti-SAA1α antibodies using in-house ELISA. IVIg, intravenous immunoglobulin; SAA, serum amyloid A.
Katja Lakota (329716) +6 more
core +1 more source
Anti-D and intravenous immunoglobulin treatments in chronic idiopathic thrombocytopenic purpura
The aim of this prospective study was to evaluate the data from 29 patients diagnosed as chronic refractory idiopathic thrombocytopenic purpura (ITP) treated with anti-D immunoglobulin and intravenous immunoglobulin G (IVIG).
Gürkan E. +4 more
core +1 more source
Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro +6 more
wiley +1 more source
Rhesus conflict during pregnancy: what one need to know
Rhesus-conflict is a pathological condition that manifests itself in the formation of antibodies against fetal erythrocytes in the body of pregnant woman due to the incompatibility of maternal and fetal Rh-factors.
B. I. Ошовський
doaj +1 more source
ABSTRACT Objective Facioscapulohumeral muscular dystrophy (FSHD) is one of the most debilitating and common muscular dystrophies. Despite its severity, no approved therapy exists for FSHD patients. However, several therapeutic candidates are currently under development, and some have recently entered clinical trials, marking the need for reliable ...
Mustafa Bilal Bayazit +11 more
wiley +1 more source
Human immunoglobulin and human albumin products can negatively affect patients’ health. The residual content of haemagglutinins, anti-D antibodies, prekallikrein activator, as well as the level of anticomplementary activity, are controlled during both ...
O. G. Kornilova +3 more
doaj +1 more source

